SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " ab8939 " 4 found 🔀 AI-powered Shuffle
AB Science provides an update on its development plan and financial calendar following a sponsor Good Clinical Practice inspection
PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON ITS DEVELOPMENT PLAN AND FINANCIAL CALENDAR FOLLOWING A SPONSOR GOOD CLINICAL PRACTICE INSPECTION Confirmation of the relevance of having, among the first decisions of the new management, given priority to the development of a new quality management system Expected resumption of the AB8939 phase 1 (acute myeloid leukemia) in the first quarter of 2027, followed by the masitinib phase 3 (amyotrophic lateral sclerosis) in the last quarter of 2027, subj
Lamborghini's most extreme car just sold out its future
Scarcity is the oldest pricing trick in luxury, and it only works when the scarcity is real. Anyone can print “limited edition” on a box. Very few companies can cap production at a hard number, refuse to move it, and still watch buyers pay a premium for the privilege of waiting a year to take ...
AB Science cuts three trials in pipeline reset
French biotech AB Science is discontinuing three masitinib trials as it concentrates its clinical resources on an ALS phase 3 programme and the early-stage development of AB8939 in acute myeloid leukaemia.
AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML
PRESS RELEASE AB SCIENCE REPORTS COMPLETION OF THE STEP 3 OF PHASE 1, EVALUATING THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA THE COMBINATION OF AB8939 WITH VENETOCLAX GENERATED A 67% OVERALL RESPONSE RATE (ORR) AND A 100% DISEASE CONTROL RATE (DCR), WITH NO DOSE-LIMITING TOXICITIES (DLT) OBSERVED, IN A POOR-PROGNOSIS POPULATION WITH ADVERSE GENETICS TREATED IN THE SECOND - TO FOURTH-LINE RELAPSED OR REFRACTORY SETTING Paris, June 2